11 Best Guru Stocks to Buy According to Wall Street Analysts

5. Corcept Therapeutics Incorporated (NASDAQ:CORT)

Number of Hedge Fund Holders: 29

Average Upside Potential: 117.48%

Corcept Therapeutics Incorporated (NASDAQ:CORT) is an American biopharmaceutical company focused on developing treatments for endocrine, oncologic, metabolic, and neurological conditions. Their approved drug, Korlym, helps manage high blood sugar in adults with Cushing’s syndrome. CORT is one of the best Guru stocks to invest in, with an average upside potential of 117% as of April 18.

On April 3, Piper Sandler raised the price target on Corcept Therapeutics Incorporated (NASDAQ:CORT) from $128 to $131 and maintained an Overweight rating on the stock after strong Phase III results for relacorilant in treating platinum-resistant ovarian cancer (PROC). Piper Sandler sees PROC as a billion-dollar market that could play a big role in Corcept’s future growth. The company plans to file for US approval in Q3 2025, followed by a submission in the EU.

Corcept Therapeutics Incorporated (NASDAQ:CORT) set records for both new Korlym prescribers and patients in the fourth quarter of 2024. As awareness of hypercortisolism grows and more people are being screened, the company expects continued growth in its Cushing’s syndrome business. Revenue for the quarter reached $181.9 million, up from $135.4 million in Q4 2023. Total revenue for the year came in at $675 million, compared to $482.4 million last year. Net income for the quarter was slightly lower at $30.7 million, but full-year net income increased to $141.2 million. Corcept ended the year with $603.2 million in cash and investments and used $38 million for stock buybacks and employee stock options.

According to Insider Monkey’s Q4 data, 29 hedge funds held long positions in Corcept Therapeutics Incorporated (NASDAQ:CORT), up from 20 funds in the last quarter. Jim Simons’ Renaissance Technologies was the leading position holder in the company, with nearly 6.2 million shares worth $312.3 million.